Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2004

View Archived Issues

Raloxifene not associated with an increase in hot flushes in postmenopausal women

Statin therapy reduces cardiovascular risk in type 2 diabetes

Boehringer Ingelheim present novel glucocorticoid receptor modulators

New NO-donating COX inhibitors claimed by Beta Pharma

Two novel series of IKK-2 inhibitors prepared and tested at AstraZeneca

AxyS (Celera Genomics) presents novel factor VIIa inhibitors

Novel BACE inhibitors in early development at De Novo

New inhibitors of Tau phosphorylation and their use described by Aventis

Long-term improvements found with sitaxsentan in PAH patients

Immunomodulatory effects of alpha-MSH in preclinical models of allergy and hypersensitivity

The Ig FLC antagonist F-991 shows promise for contact allergy

CS-747 reported to be a safe antiplatelet therapy in patients undergoing PCI

Dronedarone found to reduce the risk of recurrence of atrial fibrillation or flutter

Schering AG commences Angeliq roll-out across Europe

Cythera merges with Novocell

ReceptoPharm research into cobra venom potential for HIV

Bolder Biotechnology receives SBIR grants for oncology efforts

Cilansetron NDA accepted for priority review

Clearance sought to commence phase II trials of ThromboView in Canada

Intercell and Aventis extended bacterial vaccine collaboration

Enrollment completed in phase II/III trial of Dynavax HBV vaccine

PBI-1402 has confirmed activity on red blood cell progenitors

Company profile: Xerion

ZARS completes financing, proceeds to advance pipeline

Remoxy cleared to enter U.S. clinical studies

Icagen receives milestone payment for ICA-17043 progress

PTC Therapeutics awarded grant for Duchenne muscular dystrophy research

University of Kansas and Bioqual researchers describe a novel, orally active male contraceptive

Inhibitor of TNF-alpha converting enzyme discovered at BMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...